• MK-571 Workflows for Leukotriene Research

  2026-09-23

  Use MK-571 (L-660,711) to probe cysteinyl leukotriene signaling in airway and inflammation models, while designing separate controls for its MRP1-inhibitory activity. Practical workflows below cover compound handling, receptor assays, transporter-aware interpretation, and common troubleshooting decisions.

• hiPSC Intestinal Organoids for Pharmacokinetics

  2026-09-23

  Saito and colleagues developed a direct three-dimensional cluster-culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The resulting organoids could be propagated, cryopreserved, and differentiated into intestinal epithelial cells with enterocyte CYP enzyme and transporter activities relevant to oral drug disposition.

• Erastin: Practical Ferroptosis Workflows

  2026-09-22

  Use Erastin as a genotype-aware ferroptosis inducer for reproducible tumor-cell redox studies, then extend the workflow to macrophage antigen-presentation assays. This guide combines solution handling, quantitative dosing, orthogonal readouts, and a practical interpretation of emerging ferroptosis-immunity research.

• BIBP 3226 and the Adipose-Neural Axis

  2026-09-22

  A translational framework for using BIBP 3226 trifluoroacetate to interrogate NPY/Y1R signaling in adipose-neural models of cardiac arrhythmia, while preserving mechanistic rigor across anxiety, analgesia, and cardiovascular research.

• 2'3'-cGAMP: A Practical STING Assay Workflow

  2026-09-21

  Use 2'3'-cGAMP (sodium salt) as a receptor-proximal STING benchmark to separate DNA sensing, STING activation, and downstream interferon defects. This workflow translates findings from surgical brain injury research into controlled cell assays, pathway epistasis experiments, and compound-screening strategies.

• O-GlcNAcylation Rewires Glycolysis for Bone Formation

  2026-09-21

  The reference study identifies O-GlcNAcylation as a metabolic mechanism that connects Wnt signaling to aerobic glycolysis and osteoblast differentiation. Its central finding is that Wnt3a stabilizes PDK1 through O-GlcNAcylation at Ser174, offering a mechanistic framework for interpreting glucose metabolism as an active regulator of bone anabolism rather than a passive energy source.

• Indazole/Indole Glucagon Receptor Antagonists

  2026-09-20

  This 2015 study describes indazole- and indole-based glucagon receptor antagonists derived from the MK-0893 program and optimized through focused structure–activity relationship studies. Several compounds showed strong in vitro activity and favorable rat pharmacokinetics, while GRA 16d reduced glucagon-driven glucose elevation in human glucagon receptor mouse models.

• hiPSC Intestinal Organoids for Pharmacokinetic Studies

  2026-09-19

  Saito and colleagues established a direct three-dimensional culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The resulting organoids could be cryopreserved, differentiated into intestinal epithelial cells, and used to model CYP-mediated metabolism and transporter activity relevant to oral drug disposition.

• Lactate–H3K18la Axis Drives HCC Immune Resistance

  2026-09-18

  A 2026 Cancer Biology & Medicine study identifies a lactate-responsive H3K18la–KIF20A–c-Myc–PD-L1 pathway that links glycolytic metabolism to immune checkpoint resistance in hepatocellular carcinoma. Its combination of patient cohorts, chromatin profiling, T-cell co-culture, and xenograft experiments supports glycolysis inhibition as a strategy for restoring anti-PD-1 sensitivity, while leaving important questions about clinical translation unresolved.

• Kidney Progenitor Assembloids for Disease Modeling

  2026-09-18

  Huang et al. developed mouse and human kidney progenitor assembloids that reproduce key spatial relationships between nephron and collecting-system progenitors, improving cellular complexity, maturation, and function over conventional kidney organoids. Their genome-edited, in vivo-grown PKD2-deficient human model also captured cystic disease features and interactions among epithelial, stromal, and macrophage populations.

• BOP Reagent: From Coupling Chemistry to Prodrugs

  2026-09-17

  A translational perspective on how BOP reagent supports controlled carboxyl activation, phenyl ester preparation, and peptide-like conjugate workflows, using a carrier-free ROS-responsive triterpene prodrug study in oral squamous cell carcinoma as a strategic case study.

• DT-TRAP: Low-Temperature Target Recognition

  2026-09-17

  The reference study introduces dose- and temperature-optimized target-responsive accessibility profiling (DT-TRAP), showing that a simplified three-dose design and 4 °C incubation can improve the specificity of chemoproteomic target recognition. Its results provide a practical framework for reducing nonspecific interactions and identifying ligand-associated proteins in complex proteomes.

• GLP-1 (9-36) Amide: Research Guide

  2026-09-16

  GLP-1 (9-36) amide is a glucagon-like peptide-1 receptor antagonist used to interrogate GLP-1 receptor signaling in controlled research systems. Its product specifications, storage requirements, and interpretation limits should be separated from peer-reviewed evidence on related GLP-1 receptor ligands.

• Rethinking GLP-1R Antagonism in Translational Research

  2026-09-16

  GLP-1 (9-36) amide can serve as a practical perturbation tool for resolving glucagon-like peptide-1 receptor signaling in complex metabolic systems. By integrating receptor-crosstalk controls, careful peptide handling, and translational assay logic, researchers can move beyond simple antagonist claims toward more reliable interpretation of GLP-1 receptor pathway data.

• Indazole/Indole Glucagon Receptor Antagonists: SAR

  2026-09-15

  This 2015 Bioorganic & Medicinal Chemistry Letters study introduced indazole- and indole-based glucagon receptor antagonists derived from the pyrazole lead MK-0893. Systematic modification of the indazole C3, C6, and N1-benzylic positions produced compounds with strong in vitro activity, favorable rat pharmacokinetics, and acute glucose-lowering effects for GRA 16d in glucagon receptor humanized mouse models.

8403 records 1/561 page Next 12345 下5页 Last page